Cipla announced the launch of Ciposcillo®, an advanced oscillometer designed for accurate and precise assessment of respiratory mechanics. The device enables early diagnosis of obstructive airway diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Built on US FDA cleared technology and engineered for Indian clinical practice, Ciposcillo® is CDSCO approved and ISO certified.
With respiratory diseases on the rise in India, early detection and diagnosis of lung health conditions remains critical. Ciposcillo® combines precision, portability and clinically validated technology to better enable clinicians to assess patients across diverse healthcare settings. Importantly, the oscillometer can assess respiratory functions using normal, tidal breathing, eliminating the need for forceful patient effort. This makes it particularly suitable for use in elderly patients, young children, and others who may not be able to perform effort-dependent tests such as spirometry. Ciposcillo® incorporates India-specific reference values and is supported by Z-score–based interpretation for more individualized assessments, with a user-friendly interface for easy, seamless use.
Speaking on the launch, Achin Gupta, MD and Global CEO, Cipla said, “At Cipla, innovation is central to how we address patient needs across the healthcare continuum – from therapies to diagnostics. With Ciposcillo®, we are not only bringing advanced diagnostic technology closer to clinicians to empower better decision-making, but also enabling a simpler, effort-independent approach that makes it accessible across age groups and care settings. This is another step in our journey to improving lung health outcomes and delivering on our purpose of Caring for Life.”
Ciposcillo® expands Cipla’s diagnostic toolkit available to physicians, reinforcing the company’s broader commitment to advancing disease detection and management, especially in high-burden areas such as respiratory health.
